Mitral regurgitation (MR) is a common valvular heart disease characterized by abnormal reversal of blood flow from the left ventricle (LV) into the left atrium (LA). Chronic severe MR has both pathophysiologic and clinical consequences. The pathophysiologic results of MR are volume overload and resultant LV and LA remodeling and subsequent impairment in LV function. If the severe MR is uncorrected it would lead to excess mortality and morbidity. Even in asymptomatic patients with severe MR eventually need surgery during their follow up to evade indisposed consequences like LV dysfunction, arrhythmias, atrial fibrillation and excess mortality rate. The timing of surgical intervention depends on the consequences of existing severe MR as that compared with surgical outcomes.
The timing of surgical correction for MR depends chiefly on three factors: clinical symptoms, LV function and the severity of MR. In term of waiting symptoms, the surgery has changed considerably from a relatively passive response to the development of severe symptoms, to an early surgery concept preceding the signs of LV dysfunction. This because clinical symptoms can remain absent or minimal despite severe regurgitation caused by adaptive remodeling of LV and left atrium, or because of patient adaptation of the disease. Thus, in chronic severe MR, there should be no waiting for LV function to decline before intervening, because the long-term results of that approach are not gratifying.

Recent data underscored that mitral surgery is associated with a considerably decreased subsequent risk of mortality and heart failure. The reduction in the risk of death associated with surgery is greater among patients with a larger effective regurgitant orifice (ERO) assessed echocardiographically than among those with a smaller ERO and results in normalization of the life expectancy. These data provide a firm basis for considering surgery in patients with
individual patient. MR caused by an anatomic abnormality of the leaflets and chordae is termed primary regurgitation, while MR caused by a process primarily affecting the left ventricle is termed secondary MR. 1 MR can be classified as mild, moderate and severe degree. Presently, in term of etiology, it divides into organic and functional MR. Organic MR means the abnormality is at the valve apparatus itself; however, in functional MR, the source of abnormality is at the poor function of myocardium and secondary to a dilated mitral annulus from dilatation of the left ventricle (LV). The ordinary causes of organic MR comprise mitral valve prolapse, rheumatic heart disease, coronary artery disease, infective endocarditis, certain drugs and collagen vascular disease. 1, 2 The ultimate goal of patient management is obviously no longer the relief of limiting symptoms but the achievement of an optimal long-term outcome with regard to mortality and morbidity. 3 Yet, the management of MR and indications for surgery are still controversial. Previous outcome studies showed that patients with organic MR who have symptoms or a reduced ejection fraction are at high risk, warranting mitral surgery. Conversely, the clinical outcome among patients with asymptomatic MR is poorly defined, and criteria defining high-risk subgroups are uncertain. 4 Such subgroups are important to identify as technical improvements in surgery allow the restoration of patients' life expectancy. 5 Thus, surgery may be acceptable in high-risk patients with asymptomatic MR under medical management. In patients with primary MR, there may be an interval of several years between the diagnosis of significant MR and onset of symptoms. In addition to development of symptoms, the two major concerns in patients with asymptomatic primary mitral valve disease are the risk of sudden death and the risk of irreversible left ventricular dysfunction. 6 
Progressiveness of MR
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Chronic MR imposes a volume load on the left ventricle. In response to this volume load, initially the left ventricle empties more completely. Over time, left ventricular dilation maintains a normal forward cardiac output despite the regurgitant flow into the left atrium in systole. Early in the disease course, left ventricular systolic function remains normal, as measured by the rate of rise in ventricular pressure (dP/dt) or by end systolic maximum elastance (Emax). However, in the long term, some patients develop an irreversible decrease in left ventricular contractility. 4 The progression of MR is essential in understanding this disease, because patients with severe MR incur a much higher mortality and morbidity than those with a milder degree of regurgitation. Furthermore, the high risk of LV dysfunction in patients with severe regurgitation has led to the suggestion that surgery should be performed early. 2, 4, 5 However, because of the paucity of data available on progression of MR, the rates of change in the degree of MR and the underlying mechanisms are not certain. 7 Major improvement of surgical techniques and surgical outcomes have led cardiologists and cardiac surgeons to become more aggressive in treating MR patients even they are asymptomatic or without LV dysfunction. Early editorial comment by Brian Griffin suggested that because MR is not a benign condition, if left without therapy, ultimately patient's morbidity and mortality increases 8 . On the other hand, however, contractile LV dysfunction may precede symptoms, and therefore evaluation of symptoms alone is inadequate in determining the time of surgery in chronic MR.
What information is required to decide a patient who would urge for surgery? There are factors that pose a big impact the outcome of patient with severe MR. Namely, symptoms, LV dysfunction and degree of MR.
Wait for patient's symptoms?
Once symptom occurs in patients with severe MR surgical intervention should be carried out. Because LV dysfunction has obviously preceded the symptoms. Patients with mild to moderate MR may remain asymptomatic and uncompromised for years, although a primary MV abnormality tends to progress over time. During this process, deleterious effects may be partially offset by beneficial compensatory changes.
For example, an increase in LV end-diastolic volume may lead to increased total stroke volume that helps restore cardiac output. Such compensation may permit a patient to remain asymptomatic for a longer period of time and even permit some patients to exercise briskly. However, prolonged severe volume overload eventually leads to LV dysfunction in most patients; typically, this occurs over the course of six to ten years in patient with chronic severe MR. 9 Asymptomatic patients with mild MR and no evidence of LV enlargement, LV dysfunction, or pulmonary hypertension can be followed on an annual basis with instructions to alert the physician if symptoms develop in the interim. Yearly echocardiography is not necessary unless there is clinical evidence that MR has worsened.
In patients with moderate MR, clinical evaluation including echocardiography should be performed annually and sooner if symptoms occur. In asymptomatic patients with severe MR, clinical evaluation and echocardiography should be performed every six to 12 months to assess symptoms or transition to asymptomatic LV dysfunction. 6, 7, 9 Waiting for severe symptoms is also creating problems, because symptoms always follows LV dysfunction. Severe symptoms associated with worse long-term survival and excess incidence of heart failure. The more severe pre-operative symptoms the lower post-operative EF and the higher incidence of heart failure during follow up (figure 2). When symptoms as a predictor, there is excess mortality in patients operated in with severe symptoms but no excess mortality in patients who had no or minimal symptoms, suggesting patients operated at an early stage with minimal symptoms (NYHA class I-II) have a better survival that patients with severe symptoms.
Wait for LV dysfunction?
Although interpretation of LV ejection fraction in patients with severe MR is difficult because the loading conditions facilitate ejection, several studies indicate that preoperative ejection fraction is an important predictor of postoperative survival in patients with chronic MR. 7,9,10 Ejection fraction in a patient with MR with normal LV function is usually >60%. Conversely, postoperative LV function is lower and survival reduced in patients with a preoperative ejection fraction <60% compared with patients with higher ejection fractions. 2 Because LV end-systolic dimension (or volume) may be less load dependent than ejection fraction, it can be used in timing of MV surgery. The guidelines suggest that end-systolic dimension (ESD) should be less than 40 mm preoperatively to ensure normal postoperative LV function. 1, 2, 9 Wait for MR became severe? Grading of mitral regurgitation is essential to justify the severity of MR in which surgical intervention may be offered to patients with severe MR even in the absence of overt LV dysfunction. Development of noninvasive quantitative Doppler echocardiography has transformed diagnostic approaches. Quantitative methods include assessment of regurgitant volume, regurgitant fraction and effective regurgitant orifice and the PISA method. MR is classified as severe when the regurgitant volume >60 ml/beat, Regurgitant fraction > 50% and ERO > 40 mm 2 (Table I) .
A study of Thomson and his colleagues suggested that the important proof is the presence of severe regurgitation as a potent indicator of timing of surgery. Because once severe regurgitation presented, the LV myocardial deterioration might obscurely occurred. 6 Even patients without symptom or LVD, surgical intervention should be considered early in the course of MR. The similar results has been revealed by Enrique-Sarano and his colleagues with a prospective study comprised of 456 patients with asymptomatic organic MR. 4 
Surgical Intervention
The operative risks and improvements are important considerations in the appraisal of the timing of surgery. The operative mortality is of considerable importance but was too high to consider surgery in asymptomatic patients in the past. Thus, previously, surgical treatment of MR was avoided in patients with severe LV systolic dysfunction owing to concern about operative risk and peri-operative complications. 1,2 However, for patients with organic MR, operative mortality was considerably decreased at present. 9 More recently, with improvements in surgical techniques and increased knowledge of the benefit of cardioproctective regimen makes mortality rates to decline gradually. thought. 10, 11 Additionally, clinical management is difficult and subject to controversy. Delaying surgical correction until symptoms appear is problematic, since the outcome may be suboptimal at that stage, with an excess risk of postoperative mortality and left ventricular dysfunction. Hence, it has been suggested that surgery for organic MR should be considered while patients are asymptomatic.
Enrique-Sarano and his colleagues reported that the reduction in the risk of death associated with surgery is greater among patients with a larger effective regurgitant orifice (EOA) than among those with a smaller effective orifice and results in normalization of the life expectancy. 2, 7 These data provide a firm basis for considering surgery in patients with asymptomatic MR who have an effective regurgitant orifice of at least 40 mm 2 . However, since the risk of atrial fibrillation increased after surgery, a clinical trial of surgery in such patients is essential. Therefore, quantitative grading of MR according to recent guidelines permits risk stratification of patients with isolated, asymptomatic, organic MR and should be part of the clinical decision-making process. 7 Current guidelines recommend surgery even if symptoms are still mild or when asymptomatic patients develop early signs of LV dysfunction, pulmonary hypertension, or atrial fibrillation. 12 Within the background of ongoing controversy about the management of asymptomatic patients with severe degenerative MR. Rosenhek et al reported a study of watchful and wait of patients with asymptomatic till the criteria of symptom occur. 3 Excellent outcome was achieved when patients were followed up carefully until either symptoms developed or until asymptomatic patients reached currently proposed criteria for surgery with regard to LV size, LV function, and pulmonary hypertension or until they developed recurrent atrial fibrillation.
The latest agreement among experts is patients who undergo surgery when already markedly symptomatic and those with reduced preoperative LV function were found to have particularly poor outcomes. [1] [2] [3] 12, 13 However, the price of maintaining normal left ventricular function and therefore survival in chronic asymptomatic MR is vigilance. 8 The current guidelines for managing patients with severe chronic MR provide an adequate margin of safety to the patient when followed rigorously and conscientiously, including serial echocardiographic examinations, in experienced hands.
The guidelines offer a management strategy algorithm for patients with chronic severe MR. The algorithm outlines the clinical steps to take depending on the absence or presence of symptoms, the status of LV function, and more. 10, 12 For optimal survival, the guidelines emphasize that, unlike the timing of aortic valve replacement for aortic regurgitation, LV ejection fraction should not be allowed to fall into the lower limit of normal in patients with chronic MR. However, clinicians often face the question as to whether the patient with advanced LV dysfunction is still a candidate for surgery. The guidelines recommend that surgery still be considered because even though a patient may experience persistent LV dysfunction, surgery will likely improve symptoms and prevent further LV Function deterioration.
